Legend Biotech Corp (LEGN) Form 6-K — Oct 15, 2026
Legend Biotech announced FDA clearance of its IND application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell malignancies. The company says this is the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance. LB2501 is an off-the-shelf, single-infusion therapy built on Legend's proprietary TaVec lentiviral vector platform, designed to generate CAR-T cells directly within the patient and potentially avoid the manufacturing steps of conventional autologous CAR-T. It is already in a Phase 1 study in China (NCT07002112).
Key figures
- Employees
- 3000
- China trial nct
- NCT07002112
- Bnhl share of malignant lymphomas percent
- 90
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.